Galcanezumab - CaLiGraph

CaLiGraph

Property	Value
rdf:type	owl:NamedIndividual Antimigraine drug Monoclonal antibody Signaling peptide/protein receptor modulator Therapeutic monoclonal antibody Eli Lilly and Company brand Drug granted breakthrough therapy designation
rdfs:label	Galcanezumab
owl:sameAs	dbr:Galcanezumab
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Signaling_peptide_receptor http://en.wikipedia.org/wiki/Category:Antimigraine_drugs http://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies http://en.wikipedia.org/wiki/Category:Eli_Lilly_and_Company_brands http://en.wikipedia.org/wiki/Calcitonin_gene-related_peptide_receptor_antagonist http://en.wikipedia.org/wiki/Category:Monoclonal_antibodies http://en.wikipedia.org/wiki/List_of_signaling_peptide/protein_receptor_modulators http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation
skos:prefLabel	Galcanezumab
skos:altLabel	galcanezumab
clgo:alternativeName	Emgality
clgo:casNumber	1578199-75-3
clgo:drugbank	DB14042
clgo:fdaUniiCode	55KHL3P693
clgo:kegg	D10936
clgo:medlinePlus	a618063

About: clgr:Galcanezumab